We have to start looking at how tough the Bard1 technology is to commercialise. Results from early R&D is always an indicator of an application but trying to clinically translate research into a commercially viable test for patients is not an easy thing to do. Perhaps the Bar1 tech although good as a research application is not the horse that the company wants to back (low hanging fruit and quickest to market). How many years have BD1 been working on the Bard1 test now...Just saying...
Ann: Commencement of Legal Proceedings Against BARD1, page-56
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $65.06M | |||
| Open | High | Low | Value | Volume |
| 59.5¢ | 59.5¢ | 58.0¢ | $4.527K | 7.767K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38600 | 57.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 198 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |